Standout Papers
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC (2018)
- A Further Examination of the Molecular Weight and Size of Desoxypentose Nucleic Acid (1954)
- Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial (2019)
- Scavenger receptor-mediated adhesion of microglia to β-amyloid fibrils (1996)
- IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC (2021)
Immediate Impact
16 by Nobel laureates 15 from Science/Nature 69 standout
Citing Papers
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
2022 Standout
Lung cancer
2021 Standout
Works of Christian A. Thomas being referenced
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
2019 Standout
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Christian A. Thomas | 5184 | 2492 | 2020 | 57 | 7.7k | |
| Charles Eigenbrot | 2319 | 615 | 4048 | 120 | 8.3k | |
| Matthew D. Hall | 5193 | 582 | 4785 | 172 | 11.2k | |
| Željko Vujašković | 1415 | 2104 | 2919 | 165 | 9.0k | |
| Jakub Gołąb | 1623 | 4302 | 2860 | 156 | 10.2k | |
| John M. Koomen | 2152 | 549 | 5484 | 201 | 8.3k | |
| Matthias Eder | 3263 | 5934 | 2974 | 191 | 12.9k | |
| Barbara A. Foster | 1981 | 1971 | 3560 | 138 | 8.9k | |
| Danuta S. Kalinowski | 3477 | 436 | 3324 | 107 | 8.5k | |
| Duncan I. Jodrell | 7140 | 931 | 3884 | 165 | 11.0k | |
| Daniel B. Longley | 4663 | 1429 | 6849 | 125 | 11.8k |
All Works
Login with ORCID to disown or claim papers
Loading papers...